Exploring BioCardia, Inc. (BCDA) Investor Profile: Who’s Buying and Why?

Have you ever wondered who the major players are behind BioCardia, Inc. (BCDA), and what motivates their investment decisions? With a recent stock price of $1.92 as of April 17, 2025, a staggering 97.74% decrease from $84.90 on April 18, 2024, understanding the investor landscape is more critical than ever. Is it institutional investors, like Susquehanna International Group, Geode Capital Management, or perhaps insiders with a deep understanding of the company's prospects? Delve into the dynamics of who is buying, selling, and holding BCDA, and explore the factors driving their confidence—or caution—in this intriguing biotech firm, especially considering the reported $7.9 million net loss in 2024, compared to $11.6 million in 2023, and revenues of only $58,000.

BioCardia, Inc. (BCDA) Who Invests in BioCardia, Inc. (BCDA) and Why?

Understanding the investor profile of BioCardia, Inc. (BCDA) involves examining the various types of investors who hold the company’s stock and their motivations. These investors range from retail investors to large institutional holders, each with different investment strategies and objectives.

Key Investor Types:

The investor base of BioCardia, Inc. (BCDA) can be segmented into several key types:

• Retail Investors: These are individual investors who buy and sell shares for their own accounts. Retail investors may be attracted to BioCardia, Inc. (BCDA) due to its growth potential in the biotechnology sector.
• Institutional Investors: These include mutual funds, pension funds, hedge funds, and other large entities that invest on behalf of their clients. Institutional investors often conduct extensive research before investing and can hold significant stakes in the company.
• Hedge Funds: These are investment partnerships that use various strategies, including leveraging and short-selling, to generate returns. Hedge funds may invest in BioCardia, Inc. (BCDA) based on short-term trading opportunities or specific events.

Investment Motivations:

Investors are drawn to BioCardia, Inc. (BCDA) for various reasons, primarily centered around the company's potential and market position:

• Growth Prospects: BioCardia, Inc. (BCDA) operates in the biotechnology industry, which is known for high growth potential. Investors may be attracted to the company's innovative technologies and pipeline of products.
• Market Position: The company's position in the regenerative medicine field may appeal to investors looking for specialized healthcare investments.

Investment Strategies:

The strategies employed by investors in BioCardia, Inc. (BCDA) can vary widely:

• Long-Term Holding: Some investors adopt a long-term holding strategy, maintaining their positions for extended periods to benefit from the company's long-term growth.
• Short-Term Trading: Other investors engage in short-term trading, aiming to profit from short-term price fluctuations.
• Value Investing: Value investors seek to invest in companies that they believe are undervalued by the market, holding the stock until the market recognizes its true value.

For further insights into BioCardia, Inc. (BCDA)'s financial standing, consider exploring Breaking Down BioCardia, Inc. (BCDA) Financial Health: Key Insights for Investors.

BioCardia, Inc. (BCDA) Institutional Ownership and Major Shareholders of BioCardia, Inc. (BCDA)

BioCardia, Inc. (BCDA) has a mix of institutional, retail, and individual investors. As of April 2025, several institutional investors and major shareholders have positions in the company. It is important to consider their roles and recent activities to understand the stock's potential trajectory. Mission Statement, Vision, & Core Values of BioCardia, Inc. (BCDA).

As of April 17, 2025, BioCardia, Inc. (US:BCDA) has 21 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 140,101 shares.

The largest shareholders include:

• Susquehanna International Group, Llp
• Geode Capital Management, Llc
• CM Management, LLC
• Vanguard Group Inc
• VEXMX - Vanguard Extended Market Index Fund Investor Shares
• FSMAX - Fidelity Extended Market Index Fund
• UBS Group AG
• Morgan Stanley
• FSKAX - Fidelity Total Market Index Fund
• FNCMX - Fidelity Nasdaq Composite Index Fund

Institutional ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds (or held) more than 5% of the company and intends (or intended) to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%.

Recent trading activity by insiders over the last 6 months include:

• SIMON H STERTZER has made 3 purchases buying 39,289 shares for an estimated $90,514 and 0 sales.
• PETER ALTMAN (President and CEO) has made 7 purchases buying 4,439 shares for an estimated $9,451 and 0 sales.
• EDWARD M GILLIS (Senior Vice President, Devices) sold 3,257 shares for an estimated $6,514.

The share price as of April 17, 2025, is $1.92 / share. Previously, on April 18, 2024, the share price was $84.90 / share. This represents a decline of 97.74% over that period.

According to WallStreetZen, BioCardia (NASDAQ: BCDA) is owned by:

• 2.67% institutional shareholders
• 4,152.13% BioCardia insiders
• 0.00% retail investors

Phillip Md Et Al Frost is the largest individual BioCardia shareholder, owning 151.63M shares representing 3,239.97% of the company. Phillip Md Et Al Frost's BioCardia shares are currently valued at $291.13M.

Changes in Ownership

Institutional ownership in BioCardia has seen some recent adjustments. While the total number of institutions holding the stock is relatively small, their activity can still influence market sentiment. For example, OSAIC HOLDINGS, INC. removed 11,189 shares (-100.0%) from their portfolio in Q3 2024, for an estimated $34,909.

In the most recent quarter, 0 institutional investors added shares of $BCDA stock to their portfolio, and 1 decreased their positions.

Impact of Institutional Investors

Institutional investors and major shareholders can significantly impact a company’s stock price and strategy. Their actions often reflect their confidence in the company’s future prospects. For BioCardia, the presence of notable institutional holders suggests a level of due diligence and belief in the company's potential, despite the inherent risks associated with clinical-stage biopharmaceutical companies.

BioCardia's inclusion in the Russell Microcap Index in June 2021 was expected to expand ownership to additional investors and enhance liquidity.

The fund sentiment score is designed to identify companies with the highest levels of institutional accumulation. The scoring model uses a combination of the total increase in disclosed owners, the changes in portfolio allocations in those owners, and other metrics. The number ranges from 0 to 100, with higher numbers indicating a higher level of accumulation to its peers, and 50 being the average.

BioCardia, Inc. regained full compliance with Nasdaq Capital Market's Listing Requirements on September 17, 2024, following successful efforts to improve its balance sheet, including raising new capital. The successful capital raise of $7.2 million strengthens their balance sheet, providing runway for ongoing clinical trials and product development. This compliance removes a significant risk factor and may attract institutional investors who were previously hesitant due to delisting concerns.

BioCardia, Inc. (BCDA) Key Investors and Their Impact on BioCardia, Inc. (BCDA)

Understanding who invests in BioCardia, Inc. (BCDA) and why can provide valuable insights into the company's potential and perceived value. Examining the profiles and recent activities of key investors can shed light on market sentiment and possible future directions for the company.

While specific, real-time data on all investors and their direct influence is generally proprietary, we can discuss the types of investors typically interested in biotech companies like BioCardia, and how investment activities are often interpreted.

Biotech companies often attract a mix of investor types, including:

• Institutional Investors: These include mutual funds, pension funds, hedge funds, and other large financial entities. Their investment decisions are often based on extensive research and analysis.
• Venture Capital Firms: These firms specialize in providing capital to early-stage companies with high growth potential.
• Individual Investors: These can range from retail investors to high-net-worth individuals interested in the potential of biotech companies.
• Strategic Investors: These are typically other companies in the healthcare or pharmaceutical industry that may invest in BioCardia for strategic reasons, such as access to new technologies or markets.

The influence of these investors can manifest in several ways:

• Stock Price Movements: Large purchases or sales of shares by institutional investors can significantly impact the stock price.
• Company Strategy: Investors with significant stakes may have the opportunity to influence company decisions, such as research and development priorities or strategic partnerships.
• Market Confidence: The presence of well-known and respected investors can boost market confidence in the company's prospects.

Recent moves by investors, such as buying or selling large stakes, are closely watched by the market as indicators of confidence or concern about the company's future. Activist investors may also take positions in the company and push for changes in management or strategy to unlock value.

For more insights into BioCardia's mission, vision, and core values, you can visit: Mission Statement, Vision, & Core Values of BioCardia, Inc. (BCDA).

BioCardia, Inc. (BCDA) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions is crucial for evaluating the potential of BioCardia, Inc. (BCDA). Here's a breakdown of how major shareholders, the stock market, and analysts view BioCardia.

Investor Sentiment:

Corporate insider sentiment appears positive. Over the past quarter, there has been an increase in insiders buying shares of BCDA compared to earlier in the year. For example, in April 2025, Peter Altman, the President & CEO, purchased 500 shares for $980.00.

Institutional ownership is present, with 21 institutional owners and shareholders holding a total of 140,101 shares. Major shareholders include:

• Susquehanna International Group, Llp
• Geode Capital Management, Llc
• CM Management, LLC
• Vanguard Group Inc

However, it is important to note that in Q3 2024, OSAIC HOLDINGS, INC. removed 11,189 shares (-100.0%) from their portfolio, estimated at $34,909.

Recent Market Reactions:

BioCardia's stock has shown mixed performance. As of April 3, 2025, the stock price declined to $2.10, with 48,401 million shares traded. The stock price as of April 17, 2025, was $1.92 per share. Previously, on April 18, 2024, the share price was $84.90 per share, representing a decline of 97.74% over that period.

However, positive two-year outcomes from the Phase 3 CardiAMP-HF study, revealed in March 2025, led to a 7.69% return over the past week, with the stock trading at $2.80 per share.

Analyst Perspectives:

Analysts generally have a positive outlook on BioCardia. The consensus rating is 'Strong Buy,' with 100% of analysts recommending a Strong Buy.

Price targets vary, but the average one-year price target for BioCardia, Inc. is $15.81. Forecasts range from a low of $6.06 to a high of $26.25. One analyst from Alliance Global Partners reiterated a Buy rating with a price target of $6.00.

Analysts emphasize that BioCardia's future hinges on the successful commercialization of its pipeline products, presenting a high-risk, high-reward investment opportunity.

Here's a summary of analyst ratings:

For additional insights into BioCardia, Inc., explore this resource: BioCardia, Inc. (BCDA): History, Ownership, Mission, How It Works & Makes Money